v3.22.2.2
NOTE 1 - BASIS OF PRESENTATION (Details) - Sangui BioTech GmbH
12 Months Ended
Jun. 30, 2022
Equity Method Investment, Ownership Percentage 90.00%
Equity Method Investment, Additional Information Effective from June 18, 2018 Sangui BioTech GmbH together with Mölnlycke Health Care GmbH (former: Sastomed GmbH) founded Sangui Know-How- und Patentverwertungsgesellschaft mbH & Co. KG (“Sangui KG”). Sangui KG is a limited partnership, with Sangui BioTech GmbH as the general partner (owing 99.8%) and Mölnlycke Health Care GmbH as a limited partner (owning 0.2%)